Vascular Closure Devices Market Forecasts to 2030 – Global Analysis By Product (Passive Approximators, Active Approximators and External Haemostatic Devices), Access Mode (Femoral Access and Radial Access), Application (Peripheral Vascular Interventions,

Vascular Closure Devices Market Forecasts to 2030 – Global Analysis By Product (Passive Approximators, Active Approximators and External Haemostatic Devices), Access Mode (Femoral Access and Radial Access), Application (Peripheral Vascular Interventions, Cerebrovascular Interventions and Other Applications), End User and By Geography

According to Stratistics MRC, the Global Vascular Closure Devices Market is accounted for $1.3 billion in 2024 and is expected to reach $2.1 billion by 2030 growing at a CAGR of 8.3% during the forecast period. Vascular closure devices (VCDs) are medical instruments designed to seal or close punctures in blood vessels, typically following catheter-based procedures like angiography or percutaneous coronary interventions. These devices are crucial for minimizing bleeding, reducing complications, and expediting recovery by facilitating faster hemostasis at the puncture site. VCDs operate through various mechanisms, including mechanical compression, tissue adhesives, or the deployment of specialized plugs or patches. By effectively sealing the vascular entry point, VCDs help prevent complications such as hematomas, bleeding, or infections, and allow patients to resume normal activities more quickly.

According to the British Heart Foundation, in 2024, there are around 620 million people living with heart and circulatory diseases across the world. According to the data by Centers for Medicare and Medicaid Services (CMS.gov) shows that in 2023, the U.S. spent approximately USD 4.7 trillion on healthcare, constituting 18% of the national economy.

Market Dynamics:

Driver:

Growing preference for minimally invasive procedures

The increasing preference for minimally invasive procedures is driving advancements in Vascular Closure Devices (VCDs), which are crucial for efficiently closing access sites after catheter-based interventions. As healthcare shifts towards less invasive techniques to reduce patient recovery times and minimize complications, VCDs are evolving to meet these demands. Modern VCDs offer improved safety, efficacy, and patient comfort by using advanced materials and technologies to ensure rapid and secure closure of vascular access points. This trend reflects a broader movement in medicine towards procedures that involve smaller incisions, less pain, and quicker returns to normal activities.

Restraint:

Clinical risks and complications

Vascular Closure Devices (VCDs) are designed to close femoral artery access sites after catheter-based procedures, aiming to minimize bleeding and expedite recovery. Their use carries clinical risks and complications that can impede their effectiveness. Key risks include infection, hematoma formation, and vascular injury, which can lead to complications like limb ischemia or thrombosis. There is also the potential for device-related issues such as inadequate sealing or device migration, which can cause bleeding or arterial damage.

Opportunity:

Rise in cardiovascular procedures

As the volume of procedures like angioplasty and stent placements rises, the demand for efficient, safe, and effective VCDs has surged. Modern VCDs are designed to provide faster hemostasis, reduce complications such as bleeding and infection, and shorten recovery times. Innovations in VCD technology include improved materials for better tissue sealing, enhanced ease of use for clinicians, and designs that accommodate various vascular access sites. These advancements not only facilitate quicker patient recovery but also enhance procedural efficiency, aligning with the growing complexity and frequency of cardiovascular interventions.

Threat:

Intellectual property challenges

The vascular closure device (VCD) industry faces significant challenges due to intellectual property (IP) issues. Patent disputes and restrictive IP claims can stifle innovation by preventing new entrants from developing or marketing their own devices. Established companies often hold broad patents that cover fundamental technologies, creating barriers for startups and other competitors. This situation can lead to expensive legal battles, which divert resources away from research and development. Stringent IP regulations can delay the introduction of new, potentially better devices to the market, limiting advancements in patient care. The result is a constrained market where innovation is slowed, and the cost of devices may remain high, impacting accessibility and treatment options for patients.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the vascular closure devices (VCDs) market due to disruptions in elective procedures and a shift in healthcare priorities. As hospitals worldwide focused on managing severe COVID-19 cases, many non-urgent procedures, including those requiring vascular access, were postponed or canceled. This led to a temporary decline in demand for VCDs, which are used to close the arterial access site after catheter-based procedures. Supply chain disruptions and restrictions affected the production and distribution of these devices. The pandemic also accelerated the adoption of remote and less invasive diagnostic techniques, further impacting the traditional usage of VCDs.

The Active Approximators segment is expected to be the largest during the forecast period

Active Approximators segment is expected to be the largest during the forecast period. Active approximators are revolutionizing vascular closure devices by significantly improving their efficacy and ease of use. These advanced devices utilize dynamic mechanisms to securely close the puncture site left after catheterization procedures. Unlike traditional passive methods that rely on static pressure or manual manipulation, active approximators apply controlled, adjustable forces to precisely align and seal the vascular opening. This innovation enhances the device's ability to achieve a reliable closure with minimal complications, such as bleeding or infection.

The Cerebrovascular Interventions segment is expected to have the highest CAGR during the forecast period

Cerebrovascular Interventions segment is expected to have the highest CAGR during the forecast period. Cerebrovascular Interventions segment focus on increasing the precision of vascular closure, reducing complication rates, and shortening recovery times. Modern VCDs are designed with innovative features such as improved hemostatic agents and more adaptable closure mechanisms, which ensure better sealing of the access site and minimal trauma to surrounding tissues. Additionally, the incorporation of real-time imaging and advanced tracking systems allows for more accurate device placement and monitoring.

Region with largest share:

Europe region commanded the largest market share over the extrapolated period driven by the integration of cutting-edge technologies, improved medical training, and streamlined regulatory processes. Advanced VCDs, which are crucial for sealing arterial punctures after procedures like catheterizations, are benefiting from increased investment in healthcare facilities and research across the region. Enhanced infrastructure facilitates the development and deployment of innovative devices that offer greater precision, safety, and patient comfort throughout the region. Hospitals and clinics equipped with state-of-the-art tools and facilities can more effectively utilize these advanced VCDs, leading to improved procedural outcomes and reduced recovery times. These elements are boosting the regional growth.

Region with highest CAGR:

Europe region is projected to witness substantial growth during the forecast period due to the adoption of Vascular Closure Devices (VCDs) by ensuring stringent safety and efficacy standards. The European Union's regulatory framework, including the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), mandates rigorous clinical evaluations, quality control measures, and post-market surveillance for these devices. This regulatory oversight fosters innovation by encouraging manufacturers to adhere to high standards, thus driving advancements in technology and improving patient outcomes across the region.

Key players in the market:

Some of the key players in Vascular Closure Devices market include Abbott Laboratories, Boston Scientific Corporation, Cardinal Health, Inc, Endologix, Inc, GE Healthcare, HeartWare International, Inc, Medtronic PLC, Nipro Corporation, Stryker Corporation and Terumo Corporation.

Key Developments:

In June 2024, Haemonetics Corporation has announced the launch of its new VASCADE MVP XL mid-bore venous closure device. The VASCADE MVP XL system adds to Haemonetics VASCADE line of vascular closure devices by using novel collapsible disc technology with a patented resorbable collagen patch that promotes fast hemostasis.

In November 2023, Johnson & Johnson Service Inc., a biotechnology company, announced the completion of the acquisition of Laminar, Inc., a privately held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

In February 2023, the LockeT product was introduced to the market by Catheter Precision, Inc., a wholly-owned subsidiary of Ra Medical Systems, Inc. The first shipments of the product to its distributors will start right away. When a catheter is inserted through the skin into a blood artery and subsequently removed after an operation, LockeT can be utilized in combination with the closure of the percutaneous wound site.

Products Covered:
• Passive Approximators
• Active Approximators
• External Haemostatic Devices

Access Modes Covered:
• Femoral Access
• Radial Access

Applications Covered:
• Peripheral Vascular Interventions
• Cerebrovascular Interventions
• Other Applications

End Users Covered:
• Hospitals
• Cardiac Catheterization Laboratories
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements